Clinical trials: Deleterious BRCA1 Gene Mutation, open to volunteers
Breast Cancer
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
The purpose of this study is to assess whether expression of not only POLQ/Polθ, but also Shieldin complex and/or 53BP1 are correlated with primary and/or acquired resistance to PARPi (Poly(ADP-Ribose) Polymerases inhibitors) in…
- Trial name
- REPARP (NCT05378204)
- Testing
- Main study:, Sub-study:
- Where
- 25 sites in France
- Volunteers
- 120 people
- Sponsor
- Institut Claudius Regaud
Breast Cancer
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
Breast cancer is the most common cancer in women worldwide, with high mortality. About 5% to 10% of breast cancers are hereditary.
- Trial name
- PICB (NCT04960839)
- Testing
- Prophylactic contralateral breast irradiation
- Where
- 8 sites in China, Singapore
- Volunteers
- 323 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine